ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

プロプラノロール

Propranolol

HCID 4946
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
13013-17-7
標準SMILES
CC(C)NCC(O)COc1cccc2ccccc12
InChIKey
AQHHHDLHHXJYJD-UHFFFAOYSA-N
分子式
C16H21NO2
平均分子量
259.34 g/mol
単同位体質量
259.15722891

概要

Propranolol is a propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. It has a role as an anxiolytic drug, a beta-adrenergic antagonist, a vasodilator agent, an antihypertensive agent, a xenobiotic, an anti-arrhythmia drug, an environmental contaminant and a human blood serum metabolite. It is a member of naphthalenes, a secondary amine and a propanolamine. It is functionally related to a 1-naphthol.

名称と識別子

優先名称
Propranolol
IUPAC
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
現地名
プロプラノロール
英語名
Propanolol
分子式
C16H21NO2
分子量
259.34

名称と別名

propranolol525-66-6Propanololbeta-PropranololBetalongEuprovasinProprasylytReducorPropanalolAnaprilinepropranololodl-propranolol
名称をさらに表示
1-イソプロピルアミノ-3-(1-ナフタレニルオキシ)-2-プロパノール1-(1-ナフチルオキシ)-3-(イソプロピルアミノ)プロパン-2-オール1-[(イソプロピルアミノ)メチル]-2-(1-ナフチルオキシ)エタノール1-イソプロピルアミノ-3-(1-ナフチルオキシ)-2-プロパノールアブロカノール1-[(1-メチルエチル)アミノ]-3-(1-ナフタレニルオキシ)-2-プロパノールβ-プロプラノロール1-[(1-ナフチル)オキシ]-3-(イソプロピルアミノ)プロパン-2-オール1-[(1-メチルエチル)アミノ]-3-(1-ナフトキシ)-2-プロパノール1-(1-ナフトキシ)-3-(イソプロピルアミノ)-2-プロパノールプロパノロールプロプラノロールプロペラノロール1-(1-ナフチルオキシ)-3-(イソプロピルアミノ)-2-プロパノール1-(イソプロピルアミノ)-3-(1-ナフチルオキシ)-2-プロパノール1-(1-ナフチルオキシ)-3-イソプロピルアミノ-2-プロパノール1-(イソプロピルアミノ)-3-[(1-ナフチル)オキシ]-2-プロパノール1-(ナフタレン-1-イルオキシ)-3-[(プロパン-2-イル)アミノ]プロパン-2-オールAvlocardylrac-PropanololAvlocanol208-378-0
Propranololum1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol9Y8NXQ24VQ1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-CHEBI:8499DTXSID6023525

データベース識別子

CAS
13013-17-7、525-66-6
PubChem CID
4946
DTXSID
DTXSID6023525
ChEMBL
CHEMBL27
ChEBI
CHEBI:8499
UNII
9Y8NXQ24VQ
EC Number
208-378-0、235-867-6
Nikkaji
J6.653B

物性

構造計算による物性

XLogP
3
極性表面積
41.5 Ų
水素結合供与体数
2
水素結合受容体数
3
回転可能結合数
6
重原子数
19
形式電荷
0
複雑度
257

実験および物理化学的性質

Chemical Classes · 2 件

Other Uses -> Pharmaceuticals

Pharmaceutical

Drugs · 3 件

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals -> Antihypertensive drugs

Pharmaceuticals

LogP · 2 件

3.48

3.09

Solubility0.0617 mg/L at 25 °C
Human Drugs · 5 件

Antidepressants -> Beta blockers

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics

EMA approved medicines: Human medicine

Pharmaceuticals

Antianginal medicines

Melting Point96 °C
Physical DescriptionSolid
Ionization Efficiency · 6 件

Positive

3.75

2.7

Agilent XCT

Electrospray ionization

formic acid (5.3nM)

Dissociation Constants · 3 件

9.53

9.45

9.42

Collision Cross Section · 4 件

162.5 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: APCI+; Dataset: TOXCAST; Source Identifier: DTXSID3021198]

161.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

162.7 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

166.22 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
163 · 163-164 °C
沸点
402.6 °C · 402.6°C (rough estimate)
比重(密度)
1.028 · 1.0280 (rough estimate)
屈折率
1.55 · 1.5500 (estimate)
貯蔵温度
-20 °C · -20°C Freezer, Under inert atmosphere
溶解性
DMSO(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
13.84 · 13.84±0.20(Predicted)
色
ホワイトからオフホワイト
水溶解度
80.99 mg/L · 80.99mg/L(25℃)
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChIKey
AQHHHDLHHXJYJD-UHFFFAOYSA-N
SMILES
C(NC(C)C)C(O)COC1=C2C(C=CC=C2)=CC=C1
CAS データベース
525 · 525-66-6
NISTの化学物質情報
Propranolol(525-66-6)
EPAの化学物質情報
2 · 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- (525-66-6)

化学的性質

化学的特性Colorless crystals.Soluble in water and alcohol; insoluble in benzene and ether.

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory Information · 2 件

REACH registered substance: (±)-1-(isopropylamino)-3-(naphthyloxy)propan-2-ol (EC: 235-867-6)

Propranolol: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-: Human health tier I assessment
Hazards SummaryAllergic contact dermatitis reported in pharmaceutical workers; [Kanerva, p. 1830] See Oxprenolol.
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Hepatotoxicity · 1 件

Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on propranolol and are usually transient and asymptomatic, resolving even with continuation of therapy. Despite its widespread use, propranolol has not been convincingly linked to instances of clinically apparent liver injury; the few cases reported have generally occurred in patients who were receiving other well known hepatotoxic agents or were associated with elevations in serum enzymes only without jaundice.

Adverse Effects · 2 件

Skin Sensitizer - An agent that can induce an allergic reaction in the skin.

Common side effects of using propranolol include bradycardia, gastrointestinal issues, abdominal pain, nausea, erectile dysfunction, and wheezing/bronchospasms. Propranolol use can also cause drowsiness, fatigue, and cold extremities. Some extreme side effects to be aware of include allergic reactions, insulin resistance, and hallucinations. Prescribers need to explain and discuss all of the side effects before giving patients a prescription for propranolol.

Toxicity SummaryIngestion of greater than 1 g of propranolol in 24 hours can potentially be lethal and lead to profound bradycardia, bradyarrhythmia, hypotension, bronchospasm.
Drug Induced Liver Injury · 6 件

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

propranolol

Inderal®

Beta blockers

3

less-DILI-concern drugs

Effects During Pregnancy and Lactation · 2 件

◉ Summary of Use during Lactation

◈ What is propranolol?

USGS Health-Based Screening Levels for Evaluating Water-Quality · 3 件

Propranolol

Pharmaceutical

Smith, C.D. and Nowell, L.H., 2024. Health-Based Screening Levels for evaluating water-quality data (3rd ed.). DOI:10.5066/F71C1TWP

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Propranolol

0.7

3.0

The recommended dose is 10 mg to 30 mg propranolol hydrochloride three or four times daily before meals and at bedtime.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 30 mg/day, Lowest Therapeutic Dose (LTD): 0.4 mg/kg-day, and Screening Dose: 0.0001 mg/kg-day.

1-Aug-15

安全データ

hs_code
2922509090

化学と産業

薬理情報

ATC Code · 4 件

C07AA05

C - Cardiovascular system

QC - Cardiovascular system

C07AA05

Protein BindingApproximately 90% of propranolol is protein bound in plasma. Other studies have reported ranges of 85-96%.
Pharmacodynamics · 1 件

Propranolol is a beta-adrenergic receptor antagonist used to treat hypertension. Propranolol has a long duration of action as it is given once or twice daily depending on the indication. When patients abruptly stop taking propranolol, they may experience exacerbations of angina and myocardial infarctions.

Mechanism of Action · 1 件

Propranolol is a nonselective β-adrenergic receptor antagonist. Blocking of these receptors leads to vasoconstriction, inhibition of angiogenic factors like vascular endothelial growth factor (VEGF) and basic growth factor of fibroblasts (bFGF), induction of apoptosis of endothelial cells, as well as down regulation of the renin-angiotensin-aldosterone system.

Biological Half-LifeThe elimination half-life of propranolol is approximately 8 hours. The plasma half-life of propranolol is 3 to 6 hours.
Metabolism/Metabolites · 2 件

Propranolol undergoes side chain oxidation to α-naphthoxylactic acid, ring oxidation to 4’-hydroxypropranolol, or glucuronidation to propranolol glucuronide. It can also be N-desisopropylated to become N-desisopropyl propranolol. 17% of a dose undergoes glucuronidation and 42% undergoes ring oxidation.

Propranolol has known human metabolites that include (2S,3S,4S,5R)-3,4,5-Trihydroxy-6-[1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-yl]oxyoxane-2-carboxylic acid.

FDA Pharmacological Classification · 6 件

9Y8NXQ24VQ

PROPRANOLOL

Mechanisms of Action [MoA] - Adrenergic beta-Antagonists

Established Pharmacologic Class [EPC] - beta-Adrenergic Blocker

Propranolol is a beta-Adrenergic Blocker. The mechanism of action of propranolol is as an Adrenergic beta-Antagonist.

PROPRANOLOL

MeSH Pharmacological Classification · 4 件

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs used to cause dilation of the blood vessels.

Absorption, Distribution and Excretion · 4 件

Patients taking doses of 40mg, 80mg, 160mg, and 320mg daily experienced Cmax values of 18±15ng/mL, 52±51ng/mL, 121±98ng/mL, and 245±110ng/mL respectively. Propranolol has a Tmax of approximately 2 hours, though this can range from 1 to 4 hours in fasting patients. Taking propranolol with food does not increase Tmax but does increase bioavailability.

91% of an oral dose of propranolol is recovered as 12 metabolites in the urine.

The volume of distribution of propranolol is approximately 4L/kg or 320L.

The clearance of propranolol is 2.7±0.03L/h/kg in infants <90 days and 3.3±0.35L/h/kg in infants >90 days. Propranolol clearance increases linearly with hepatic blood flow. Propranolol has a clearance in hypertensive adults of 810mL/min.

Tissue LocationsLiver
Cellular LocationsMembrane
Metabolite PathwaysPropranolol Action Pathway

用途と製造

Uses · 2 件

Used as a beta-blocking agent (antihypertensive drug); [Kanerva, p. 1830]

Use (kg) in Switzerland (2009): >750

Use ClassificationPharmaceuticals

応用分野

説明Propranolol was responsible for sensitisation of workers in drug synthesis. In one case, epichlorhydrin was used for the production of both propranolol and oxprenolol.

使用Cardiac depressant (anti-arrhythmic); anti-adrenergic (β-receptor).

上流・下流製品情報

下流製品

N-ホルミルプロプラノロールプロプラノロール塩酸塩

補足説明

定義ChEBI: A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

関連反応

17 件
反応記録を作成
HRID 10485 の反応式
HRID 10485生成物として
HRID 35665 の反応式
HRID 35665生成物として
HRID 231910 の反応式
HRID 231910生成物として
HRID 328884 の反応式
HRID 328884生成物として
HRID 328886 の反応式
HRID 328886生成物として
HRID 328887 の反応式
HRID 328887反応物として
HRID 867506 の反応式
HRID 867506反応物として
HRID 892129 の反応式
HRID 892129反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート